Clinical Trial Supplies Market to Reach USD 9.7 Billion by 2035, Driven by Biologics, Decentralized Trials, and AI-Powered Supply Chains

The global Clinical Trial Supplies Market is projected to grow from USD 4.6 billion in 2025 to USD 9.7 billion by 2035, expanding at a CAGR of 7.8% during the forecast period. This growth is fueled by the rising complexity of biologics and cell therapies, the expansion of decentralized clinical trial models, and increasing integration of AI and digital platforms in supply chain management.

MarketGenics, a leading research firm, highlights clinical trial supplies as a critical backbone of global drug development, enabling precision logistics, compliance, and patient-centered trial participation in an era of accelerated therapeutic innovation.

Get the Detailed Industry Analysis (including the Table of Contents, List of Figures, and List of Tables) - from the Clinical Trial Supplies Market Research Report: https://marketgenics.co/press-releases/clinical-trial-supplies-market-01651

Recent Developments Shaping the Market
DHL Scales Healthcare Logistics Infrastructure

In May 2025, DHL Group announced a €3.5 billion multiyear capex plan and a new €300 million cost-reduction program, alongside the opening of a 32,000 m2 certified pharma hub near Frankfurt to expand controlled-temperature warehousing and trial supply services.

UPS Expands Cold-Chain Capabilities

In April 2025, UPS acquired Andlauer Healthcare Group for USD 1.6 billion, strengthening its global temperature-controlled logistics and cryogenic handling solutions, especially for biologics and cell therapies.

Catalent Advances Decentralized Supply Models

In January 2024, Catalent launched a direct-to-patient delivery and telehealth-friendly packaging solution, addressing growing demand for decentralized and hybrid trial models that improve patient retention.

Clinical Trial Supplies Market Forecast 2035
The market is set to create an incremental opportunity of USD 5.1 billion between 2025 and 2035.

North America will remain the largest market, supported by advanced trial infrastructure, FDA-regulated compliance, and a strong pipeline of oncology and cell therapy trials.

Asia-Pacific will record the fastest growth, driven by government-backed trial ecosystems in India and China and the increasing presence of global CROs.

Europe will sustain steady expansion with strong biologics R&D and a robust cold-chain network.

By 2035, AI-enabled, patient-centric supply chains will define global trial logistics, minimizing delays, ensuring compliance, and improving trial efficiency.

To know more about the Clinical Trial Supplies Market - Download our Sample Report: https://marketgenics.co/download-report-sample/clinical-trial-supplies-market-01651

Key Drivers, Challenges, and Opportunities
Driver - Complexity of Biologics and Personalized Medicine

The surge in biologics, cell, and gene therapies is reshaping supply needs. Lonza and Marken have expanded cryogenic storage and ultra-low temperature logistics to support these next-generation therapies.

Restraint - High Costs in Cold-Chain and Cross-Border Compliance

Advanced cryogenic handling systems remain cost-intensive, creating barriers for small- and mid-size biotech firms. Marken noted the heavy financial burden of maintaining global CAR-T logistics despite surging demand.

Opportunity - Growth of Decentralized Clinical Trials (DCTs)

Direct-to-patient supply chains, integrated inventory tracking, and telemedicine-enabled packaging are transforming participation models. These innovations open opportunities for providers who can deliver patient-specific supply models at scale.

Key Trend - AI and Digitalization in Trial Supply Chains
AI-driven supply chain management is emerging as a game-changer.

In March 2024, Parexel and Microsoft Azure introduced AI-based predictive analytics for oncology trials, enabling precise forecasting of supply demand and real-time risk mitigation.

Digital platforms, blockchain-based compliance tools, and smart packaging are reducing inventory wastage, trial delays, and regulatory risks, making AI a cornerstone of future trial supply strategies.

Buy Now: https://marketgenics.co/buy/clinical-trial-supplies-market-01651

Segmental Insights
Phase III Trials Drive Peak Demand (~47% share in 2025)

Phase III trials involve the largest patient populations, longest durations, and most complex multi-country logistics, fueling demand for high-volume packaging, temperature-controlled shipping, and compliance monitoring.

Decentralized and Hybrid Trials Fuel New Models

Suppliers are increasingly offering direct-to-patient (DTP) and home delivery solutions, with adaptive trial designs requiring flexible supply systems that can scale dynamically across regions.

Regional Highlights
North America:

Leads with ~59.7% share (USD 2.7 billion in 2025), powered by strong R&D infrastructure, FDA-regulated compliance frameworks, and large volumes of oncology and rare-disease trials.

Example: Thermo Fisher's 2024 facility expansion in Kentucky to manage complex multi-country biologics trials.

Asia-Pacific:

Fastest-growing region, supported by rapid patient recruitment in India and China, CRO expansion, and increasing clinical trial outsourcing.

Europe:

Growth led by biologics cold-chain investments and strong regulatory frameworks (EMA compliance).

Competitive Landscape
The market is moderately consolidated, with Tier-1 leaders holding ~45% share in 2025.

Tier 1 Leaders

Thermo Fisher Scientific (Fisher Clinical Services)

Catalent

PCI Pharma Services

Almac Group

UPS/Marken

Lonza

Parexel

Tier 2 Players

Clinigen, Eurofins, Vetter Pharma, Cambrex, Movianto

Tier 3 Players

Biocair, KLIFO, Sentry BioPharma

Competition is intensifying as providers integrate cold-chain, AI-enabled tracking, and patient-centric models to gain market leadership.

Get a preview of our Clinical Trial Supplies Market Playbook - your guide to GTM strategy, competitive intelligence, supplier dynamics, and Consumer Behavior Analysis: https://marketgenics.co/playbook/clinical-trial-supplies-market-01651

Future Outlook
By 2035, the clinical trial supplies market will transform into a digitally driven, patient-centered ecosystem, where real-time analytics, sustainable packaging, and decentralized distribution models define the industry.

Key growth areas include:

AI-based demand forecasting and compliance management

Smart packaging and blockchain for real-time transparency

Cryogenic logistics for cell and gene therapies

Patient-centric DTP and home-delivery trial supply systems

This evolution will position the clinical trial supplies sector as a strategic enabler of global drug development, ensuring speed, compliance, and equity in life sciences innovation.

Prominent Companies Operating in the Global Clinical Trial Supplies Market:
Thermo Fisher Scientific, Catalent, PCI Pharma Services, Almac Group, UPS/Marken, Lonza, Parexel, DHL Group, Clinigen, Eurofins, Vetter Pharma, Cambrex, Movianto, Biocair, KLIFO, Sentry BioPharma.

About Us

MarketGenics is a global market research and management consulting company empowering decision makers across healthcare, technology, and policy domains. Our mission is to deliver granular market intelligence combined with strategic foresight to accelerate sustainable growth.

We support clients across strategy development, product innovation, healthcare infrastructure, and digital transformation.

Contact:

Mr. Debashish Roy

MarketGenics India Pvt. Ltd.

800 N King Street, Suite 304 #4208, Wilmington, DE 19801, United States

USA: +1 (302) 303-2617

Email: sales@marketgenics.co

Website: https://marketgenics.co

This release was published on openPR.